- You've seen large price differences between countries and want to understand the underlying reasons
- You're trying to compare clinic quotes without being misled by how the numbers are presented
- You want to know whether a lower starting price reflects worse treatment or a structurally different system
- You need to understand how donor type and legal rules change the price range
Two separate cost questions
When patients compare prices across countries, two different issues often get mixed up. The first is why one country's starting price differs from another. The second is why the final bill ends up higher than the initial quote.
This page covers the first question. The hidden costs page covers what gets added later during treatment.
Most confusing price comparisons mix three separate problems at once: base clinic package vs total expected cost; one treatment model vs another; and an anonymous-donor market vs an identifiable-donor market. These are different variables. Changing any one of them changes what the quoted price actually represents.
- If you need identifiable donation, your options narrow to Portugal, UK, or Denmark. All three sit at or above the median base price in the covered set.
- If you're comparing a quote that uses a donor matched for your cycle with an egg-bank quote, the cost structures are different.1 A direct price comparison needs context before it's meaningful.
- If keeping costs low is the main priority, the two lowest-cost destinations, Czech Republic and North Cyprus, are both anonymous-only by law. A lower starting price does not create identifiable donors in those markets.
- If a clinic quote looks significantly lower than comparable destinations, check whether it is a base cycle fee only, or a fuller package that includes donor matching, recipient medication, and screening.
The four main drivers of starting price
Prices don't vary randomly between countries and clinics. They reflect structural differences in how treatment is built in each market. Four factors account for most of the variation you'll see.
Donor supply and availability
Where clinics draw from a large, well-established donor pool, matching costs are lower. Where supply is limited or must be supplemented from external sources, the base price rises.
Legal framework
Identifiable-donation systems have fewer donors willing to participate. That structural scarcity raises the base price. Strict screening requirements also add overhead built into the quoted fee.
Market treatment model
How treatment is structured varies by market, from fresh synchronized donor cycles to hybrid frozen-blastocyst models to egg banks. Each approach builds different operational costs into the quoted price.
Package structure
Some clinics bundle multiple components into one number. Others quote a lower base price with common additions billed separately. Two clinics can look very different in price while offering structurally similar treatment.
How donor supply and legal framework shape the price
The legal rules around donor anonymity are one of the clearest structural reasons why starting prices differ between countries.
- Spain, Czech Republic, North Cyprus, South Africa
- Anonymous rules allow clinics to recruit from a broader willing donor pool
- Lower matching and coordination cost per patient
- Lower base price reflects market structure and operating costs, not treatment quality
- Portugal, UK
- Fewer donors willing to participate when identity can be accessed later
- Structural scarcity is built into the legal framework, not the clinic
- Higher base price is a scarcity premium, not a quality premium
Denmark offers donor-type choice but operates under a strict age limit of 46, and prices tend toward the higher end of the mid-range. Greece's legal position is mixed.2 Open-ID donation is technically permitted, but most clinics operate with anonymous donor pools in practice.
How the market model affects what you're quoted
Treatment model affects the starting price, but not in a simple or predictable direction. The key issue when comparing two quotes is whether they describe the same treatment product: the same cycle type, the same donor model, and the same market context.
Czech Republic uses fresh donors almost exclusively and is one of the cheapest markets in the set. Spain also uses fresh synchronized donors and sits in the mid-range. Denmark uses a hybrid model. The UK operates four distinct pricing models. Different products, different prices.
Base price ranges by country
These are editorial estimates of the base clinic package as typically advertised, before recipient medication and other common additions.3
| Country | Est. base range3 | Donor type | Model note |
|---|---|---|---|
| Czech Republic | €4,900–€6,500 | Anonymous | Fresh donor; transparent pricing |
| North Cyprus | €5,000–€7,000 | Anonymous | Fresh donor; EU-external regulation |
| Spain | €5,500–€8,000 | Anonymous | Fresh donor, synchronized; guarantee tiers common |
| South Africa | €5,500–€8,500 (clinic + agency fees combined) | Anonymous | Split clinic and agency fees |
| Greece | €5,500–€8,000 | Mixed2 | Mainly fresh donor; banked option at some clinics |
| Portugal | €6,000–€9,000 | Identifiable | Identifiable donor by law; pricing rarely distinguishes cycle type |
| Denmark | €5,500–€9,000 | Choice | Hybrid: fresh donor, fertilize, freeze as blastocysts, transfer later |
| UK | €9,500–€13,500 | Identifiable | Four models: egg bank, fresh exclusive, egg sharing, thaw-only |
Recipient medication (endometrial preparation) adds €150–€1,050 depending on the country and protocol. It is not included in the ranges above.
The UK's higher base price reflects three structural factors: identifiable-only donors reduce supply and raise the per-donor cost; a regulated egg bank market adds compliance overhead; and NHS demand creates pricing pressure on private sector availability. It is not a quality premium. Note also that the UK is not a single-product market: egg bank, fresh exclusive, egg sharing, and thaw-only cycles each carry different price structures. A lower UK quote may mean a different product, not a better deal.
How to compare clinic quotes correctly
Before comparing two starting prices, check that you're comparing equivalent things. The questions below identify the most common sources of confusion.
- Is this a base clinic package price, or a total expected cost figure that includes agency fees?
- Is recipient medication included, or is it billed separately?
- Are donor matching and donor compensation included in the package?
- Is this a single cycle or a multi-cycle guarantee package?
- Which treatment model does this clinic use: fresh synchronized donor, hybrid frozen-blastocyst, or egg bank?
- For UK quotes specifically: is this an egg bank cycle, fresh exclusive cycle, egg sharing cycle, or thaw-only cycle? These are four distinct products, not four price tiers for the same thing.
What a lower starting price does and doesn't mean
A lower base price reflects how the market is structured in that country. It is not a straightforward quality signal in either direction. Lower cost may come from a larger, more standardized anonymous donor pool, from lower local operating costs, or from a regulatory environment that differs from EU norms.
The short version
The starting price reflects how the system behind the clinic is built. Donor supply, legal framework, treatment model, and package structure each shape what you see quoted before treatment begins. Those are country-level and market-level differences, not clinic-level ones.
Once you understand what drives the starting price, you can compare options on equal terms. What changes the final bill is a separate question, covered on the hidden costs page.
Common questions
Not directly. Price reflects system design, not outcome quality. The UK's higher cost comes from identifiable-only donors, regulated compliance overhead, and market pressure on private sector availability, not from better clinical results. Success rates depend on lab quality, embryologist experience, and your individual profile. Those factors are not captured in the base price.
Three structural reasons account for the base price difference. First, the UK requires identifiable donors by law, which reduces the number of willing donors and raises the per-donor cost. Second, it operates a regulated egg bank market with higher compliance and administrative overhead. Third, NHS demand for donor eggs creates pricing pressure on private sector availability. None of those factors reflect better clinical quality than Spain. It's also worth noting that the UK is not a uniform product market: egg bank cycles, fresh exclusive cycles, egg sharing cycles, and thaw-only cycles each carry different price structures. A UK quote at the lower end of the range likely describes a different treatment product from one at the top.
It depends on your clinical profile and how you want to manage risk. If your doctor suggests a higher chance of needing more than one cycle, a guarantee program may work out more cost-effective overall. If success on a single cycle is more likely, paying per cycle keeps upfront commitment lower. Neither option is universally better. Ask your clinic what the guarantee program specifically covers and what is excluded before comparing it to a single-cycle price.
The figures are not directly comparable, so the question is harder to answer than it looks. South Africa's stated range reflects total expected cost, including both clinic fees and agency fees. Spain's base range is a clinic-only package, before additions. You are not comparing the same scope of costs. Once you account for travel to South Africa, the apparent gap narrows significantly for most European patients. The cost structures are different, not interchangeable.
- What is included in a clinic quote varies by clinic and by cycle type. Frozen and fresh donor cycles are not directly comparable unless the included steps are clearly itemized.
- Greek law allows anonymous and identity-release donors, but most clinics still primarily operate with anonymous donor pools.
- These are editorial estimates of the base clinic package as typically advertised. Recipient medication (endometrial preparation) is not included for most countries. These are not guaranteed prices and do not include travel, accommodation, optional add-ons, or extra procedures. For South Africa, the range reflects total expected cost including clinic and agency fees.